Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Rallybio Corp (RLYB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 06/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/19/2023 |
4
| PARMAR KUSH (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 15,490 options to buy
@ $5.64, valued at
$87.4k
|
|
| 05/19/2023 |
4
| Nash Christine A (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 15,490 options to buy
@ $5.64, valued at
$87.4k
|
|
| 05/19/2023 |
4
| Boudreau Helen M (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 15,490 options to buy
@ $5.64, valued at
$87.4k
|
|
| 05/19/2023 |
4
| Hopfner Robert Lorne (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 15,490 options to buy
@ $5.64, valued at
$87.4k
|
|
| 05/19/2023 |
4
| Soteropoulos Paula (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 15,490 options to buy
@ $5.64, valued at
$87.4k
|
|
| 05/19/2023 |
4
| Liu Hui (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 15,490 options to buy
@ $5.64, valued at
$87.4k
|
|
| 05/19/2023 |
4
| HUNT RONALD (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 15,490 options to buy
@ $5.64, valued at
$87.4k
|
|
| 05/19/2023 |
4
| Chung Wendy (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 12,353 options to buy
@ $5.64, valued at
$69.7k
|
|
| 05/15/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/12/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
4
| Lieber Jonathan I (See Remarks) has filed a Form 4 on Rallybio Corp|
Txns:
| Bought 5,000 shares
@ $5.21, valued at
$26.1k
|
|
| 03/09/2023 |
4
| PARMAR KUSH (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Sold 100,000 shares
@ $8.2, valued at
$820k
|
|
| 03/09/2023 |
4
| 5AM Partners V, LLC (10% Owner) has filed a Form 4 on Rallybio Corp|
Txns:
| Sold 100,000 shares
@ $8.2, valued at
$820k
|
|
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Quarterly results|
Docs:
|
"Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects – -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025-- NEW HAVEN, Conn. March 6, 2023-- Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the fourth qu...",
"Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia -- RLYB212 Showed Rapid Elimination of Transfused, HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Clinical Findings and Safety Profile Consistent with Previously Reported Data; Continue to Support the Potential for RLYB212 as a Prophylactic Treatment for FNAIT -- -- Company Expects to Present Results at a Scientific Conference in 2023 --" |
|
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 8.6% stake in RALLYBIO CORP |
| 02/06/2023 |
4
| Uden Stephen (See Remarks) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 214,000 options to buy
@ $6.5, valued at
$1.4M
|
|
| 02/06/2023 |
4
| Ryder Steven (Chief Medical Officer) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 119,000 options to buy
@ $6.5, valued at
$773.5k
|
|
| 02/06/2023 |
4
| MACKAY MARTIN (CEO) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 214,000 options to buy
@ $6.5, valued at
$1.4M
|
|
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2023 |
3
| Lieber Jonathan I (See Remarks) has filed a Form 3 on Rallybio Corp |
| 02/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/31/2023 |
8-K
| Quarterly results |
| 01/23/2023 |
SC 13G/A
| Tekla Capital Management LLC reports a 4.6% stake in Rallybio Corp. |
| 01/05/2023 |
4
| Liu Hui (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 10,237 options to buy
@ $6.19, valued at
$63.4k
|
|
| 01/05/2023 |
4
| PARMAR KUSH (Director) has filed a Form 4 on Rallybio Corp|
Txns:
| Granted 10,344 options to buy
@ $6.19, valued at
$64k
|
|
|
|
|